Science
Most people still think of China as just a generics producer. They are dead wrong. In just one decade, China has transformed from "copycat" to cutting-edge, and now Big Pharma is licensing assets from China, not just to it.
In this episode of Game of Pharma, Lokesh sits down with Dr. Julien Willard, former senior intelligence officer, health economist, and strategy executive at Accenture and IBM, to decode what is really happening in global biotech.
In this episode, we cover:
- The Big Shift: The single biggest sign China's pharma industry has fundamentally changed.
- The Gold Rush: Why global pharmaceutical companies are scrambling for Chinese biotech assets.
- Speed to Market: How clinical trials that take years in the West are being executed in months in Shanghai.
- The US vs. China: What Western pharma should (and absolutely shouldn't) copy from China's aggressive playbook.
If you make decisions in pharma, biotech, healthcare strategy, or investment, this conversation will change how you see the next decade of the industry.
#PharmaStrategy #BiotechTrends #ClinicalTrials #HealthcareInvestment #PharmaMarketing #DrugDevelopment #Pharma #Biotech #Pharmaceuticals #LifeSciences #HealthcareInnovation
Julien's LinkedIn: https://www.linkedin.com/in/julienwillard/
Host's LinkedIn: https://www.linkedin.com/in/lokesh-sharma-7250a71a9/
Follow us on social media-
Website: https://gameofpharma.com/
Instagram: https://www.instagram.com/gameofpharma/